IL7R and acute lymphoblastic leukemia: This subgroup represents 15–20% of Ph-like ALL; this group includes alteration of IL7R, SH2B3, JAK1, JAK3, IL2B, FLT3, TYK2, and mutation in RAS pathway (KRAS, NRAS, NF1, PTPN11) [17].